Lerodalcibep · Lerochol, LIB003

What is Lerodalcibep?

Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. By inhibiting PCSK9 binding to LDLR on hepatocytes, it increases LDLR availability to clear LDL cholesterol from the blood.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Lerochol, LIB003

Drug type

Fusion protein

Targets

PCSK9, LDLR (secondary target)

Mechanism

Inhibitor of PCSK9

Pathways

LDLR-mediated cholesterol clearance

Therapy area

Metabolic

Developer

Lib Therapeutics, Inc.

In trials of

MEDP

FDA status

Approved as Lerochol (December 12, 2025), BLA761427 · FDA label

UNII

1PHP3QG5PZ

✅ FDA-approved uses

• Hypercholesterolemia, including heterozygous familial hypercholesterolemia

From the indications section of the FDA label (version of Jul 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Familial Hypercholesterolemia - HeterozygousHeterozygous Familial Hypercholesterolemia

Other drugs acting on PCSK9

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Lerochol (2026-07-28), indications

Updated Oct 3, 2026.